Bachem Holding AG focuses on peptide manufacturing as biotech demand grows

Bachem Holding AG (ISIN CH0012530207) is a Switzerland-based manufacturer of peptides and oligonucleotides used as active pharmaceutical ingredients and research-grade materials. The company positions itself as a strategic partner for biotech and pharmaceutical clients that rely on complex molecules for drug development and commercialization. For investors, the long-term demand for these building blocks is central to the Bachem story.

Peptide and oligonucleotide capacity

Bachem operates production sites in Europe and North America, with a focus on large-scale, high-quality manufacturing of regulated active pharmaceutical ingredients. Its facilities are designed to meet stringent regulatory requirements and to support customers from early-stage development through commercial supply.

The company has been investing in new capacity and technology to handle more complex peptides and oligonucleotides. These include support for highly potent compounds and specialized purification processes that are increasingly important in modern therapeutics. As biotech pipelines shift toward peptide-based drugs, additional capacity can become a meaningful competitive advantage.

Business model and customer relationships

Bachem generates revenue by supplying both clinical and commercial-scale batches of active pharmaceutical ingredients, as well as catalog products for research and development. The customer base spans global pharmaceutical groups, biotech firms, and research institutions that require reliable supply and regulatory support.

Long-term framework agreements and recurring orders are a key feature of the business model. By embedding itself into customers' development and manufacturing chains, Bachem aims to secure multi-year revenue streams from successful drug programs. This relationship-driven approach can provide visibility on future volumes once products receive regulatory approvals.

Representative products and services

At the core of Bachem's offering are peptide active pharmaceutical ingredients manufactured under strict quality standards for use in approved or investigational medicines. These may include compounds for metabolic disorders, oncology, and other therapeutic areas where peptides offer targeted mechanisms of action.

Alongside commercial APIs, Bachem supplies a broad catalog of research-grade peptides and related molecules to laboratories worldwide. This catalog business allows scientists to access a diverse range of sequences quickly, supporting preclinical projects and early discovery work. The company also offers custom synthesis services, giving customers the flexibility to obtain tailor-made peptides not available off the shelf.

Bachem stock and listing

Bachem Holding AG is listed on the SIX Swiss Exchange, reflecting its origins and headquarters in Switzerland. The stock provides investors with exposure to the peptide and oligonucleotide manufacturing segment, which is closely tied to the growth trajectory of biotech and pharmaceutical R&D activity.